

EU Moves to Improve Conditions for Embattled Biotech Sector, Ananda’s Clinical Development Pushes On, & Celadon Remains on the Brink
In response to this growing exodus of promising biotech firms, the European Union has proposed a new Biotech Act, as part of ongoing efforts by the European Commission to strengthen the continent’s biotechnology and biomanufacturing sectors, which have struggled with fragmented rules and sluggish approval processes.